A dozen or more startup companies are developing medicines from psilocybin, MDMA, ibogaine and LSD, all of which are illegal in the US, as well as from ketamine, a legal anesthetic with hallucinogenic properties...
…[like] a former managing director at Goldman Sachs who is the founder of… yet another startup… “There’s a lot of strong feeling in the psychedelic community about the sacredness of psychedelic medicine and the unholy, if not down-right rotten nature of capitalism. Sometimes it’s over-said and can feel like sanctimony, but I don’t want to reject it outright,” says Robin Carhart-Harris, Head of Centre for Psychedelic Research, Imperial College London… “I’m worried that companies will tell dubious stories to unsophisticated investors,” says Doblin. MAPs’ for-profit unit will turn over any profits to the parent nonprofit, he says: “We have been turning down investors left and right.”
Original Article (Medium):
Artwork Fair Use: Public Domain